Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Gains from Sales and Divestitures (2019 - 2023)

Historic Gains from Sales and Divestitures for Bicycle Therapeutics (BCYC) over the last 3 years, with Q4 2023 value amounting to $119144.0.

  • Bicycle Therapeutics' Gains from Sales and Divestitures rose 24041.14% to $119144.0 in Q4 2023 from the same period last year, while for Dec 2023 it was $119144.0, marking a year-over-year increase of 24041.14%. This contributed to the annual value of $119144.0 for FY2023, which is 24041.14% up from last year.
  • According to the latest figures from Q4 2023, Bicycle Therapeutics' Gains from Sales and Divestitures is $119144.0, which was up 24041.14% from $99638.0 recorded in Q3 2023.
  • In the past 5 years, Bicycle Therapeutics' Gains from Sales and Divestitures ranged from a high of $119144.0 in Q4 2023 and a low of $35000.0 during Q1 2022
  • Over the past 3 years, Bicycle Therapeutics' median Gains from Sales and Divestitures value was $78781.0 (recorded in 2023), while the average stood at $67853.8.
  • Over the last 5 years, Bicycle Therapeutics' Gains from Sales and Divestitures had its largest YoY gain of 24041.14% in 2023, and its largest YoY loss of 6282.29% in 2023.
  • Over the past 3 years, Bicycle Therapeutics' Gains from Sales and Divestitures (Quarter) stood at $83947.0 in 2019, then tumbled by 58.31% to $35000.0 in 2022, then skyrocketed by 240.41% to $119144.0 in 2023.
  • Its Gains from Sales and Divestitures stands at $119144.0 for Q4 2023, versus $99638.0 for Q3 2023 and $78781.0 for Q2 2023.